Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study

• Published in: Japanese journal of clinical oncology 2020-02, Vol.50 (2), p.129-137
• Main Authors: Demachi, Ken, Bando, Hideaki, Nomura, Hisanaga, Shitara, Kohei, Yoshino, Takayuki, Yamaguchi, Masakazu, Kawasaki, Toshikatsu
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Creatinine - blood; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Middle Aged; Oxaliplatin - therapeutic use; Oxonic Acid - therapeutic use; Renal Insufficiency - physiopathology; Retrospective Studies; Stomach Neoplasms - blood; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; Stomach Neoplasms - physiopathology; Tegafur - therapeutic use; Treatment Outcome
• ISSN: 1465-3621; 1465-3621
• DOI: 10.1093/jjco/hyz157

Abstract Backgrounds S-1 plus oxaliplatin appears effective in chemo-naïve patients with advanced gastric cancer. However, comprehensive safety and efficacy data for S-1 plus oxaliplatin is limited for patients with impaired renal function. Methods We retrospectively extracted data from advanced gastric cancer patients with normal renal function (normal group, CLcr ≥ 60 ml/min), who were treated with standard doses of S-1 (80 mg/m2) plus oxaliplatin (100 mg/m2), and patients with impaired renal function (impaired group, CLcr < 60 ml/min) who were treated with standard or reduced doses of S-1 (60 mg/m2 or 40 mg/m2) plus standard doses of oxaliplatin. Treatment efficacy and safety between the groups were compared. Results Data from 100 normal patients and 42 patients with impaired renal function were extracted. Baseline characteristics differed significantly between the two groups, including age (median, 64 vs 72 years, P